MX362702B - Compuesto de semifluorocarbono que contiene agente de contraste. - Google Patents

Compuesto de semifluorocarbono que contiene agente de contraste.

Info

Publication number
MX362702B
MX362702B MX2015013746A MX2015013746A MX362702B MX 362702 B MX362702 B MX 362702B MX 2015013746 A MX2015013746 A MX 2015013746A MX 2015013746 A MX2015013746 A MX 2015013746A MX 362702 B MX362702 B MX 362702B
Authority
MX
Mexico
Prior art keywords
semifluorocarbon
compound containing
contrast agent
containing contrast
integer ranging
Prior art date
Application number
MX2015013746A
Other languages
English (en)
Other versions
MX2015013746A (es
Inventor
Röthlein Doris
Schmitt Jürgen
keller Thorsten
Dietrich Thore
Stawowy Philipp
Fleck Eckart
Original Assignee
Braun Melsungen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braun Melsungen Ag filed Critical Braun Melsungen Ag
Publication of MX2015013746A publication Critical patent/MX2015013746A/es
Publication of MX362702B publication Critical patent/MX362702B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Signal Processing (AREA)
  • Pathology (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

La presente invención se refiere a una emulsión acuosa que comprende a) un compuesto semifluorado de fórmula I: CF3- (CF2)X-(CH2)-CH3 (I) donde x es un número entero que oscila de 1 a 8 e y es un número entero que oscila de 2 a 10, b) un triglicérido que es miscible con el compuesto semifluorado a 20°C; y c) un emulsionante.
MX2015013746A 2013-03-25 2014-03-18 Compuesto de semifluorocarbono que contiene agente de contraste. MX362702B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13160868.9A EP2783703A1 (en) 2013-03-25 2013-03-25 Semifluorocarbon compound containing contrast agent
PCT/EP2014/055398 WO2014154531A1 (en) 2013-03-25 2014-03-18 Semifluorocarbon compound containing contrast agent

Publications (2)

Publication Number Publication Date
MX2015013746A MX2015013746A (es) 2016-02-26
MX362702B true MX362702B (es) 2019-02-01

Family

ID=47913282

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013746A MX362702B (es) 2013-03-25 2014-03-18 Compuesto de semifluorocarbono que contiene agente de contraste.

Country Status (17)

Country Link
US (2) US20160000941A1 (es)
EP (2) EP2783703A1 (es)
JP (1) JP6356780B2 (es)
KR (1) KR102210774B1 (es)
CN (1) CN105142681B (es)
BR (1) BR112015017572A2 (es)
CA (1) CA2893799C (es)
DK (1) DK2978455T3 (es)
ES (1) ES2616884T3 (es)
HU (1) HUE030818T2 (es)
IL (1) IL239203A (es)
MX (1) MX362702B (es)
PL (1) PL2978455T3 (es)
PT (1) PT2978455T (es)
RU (1) RU2672588C2 (es)
TW (1) TWI652069B (es)
WO (1) WO2014154531A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2788060C (en) 2010-03-17 2017-07-11 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CN107397718A (zh) 2011-05-25 2017-11-28 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
DK2806886T3 (en) 2012-01-23 2017-06-06 Novaliq Gmbh STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES
DK2895144T3 (en) 2012-09-12 2017-03-06 Novaliq Gmbh SEMIFLUORED ALKAN COMPOSITIONS
EP2895158B1 (en) 2012-09-12 2019-11-20 Novaliq GmbH Compositions comprising mixtures of semifluorinated alkanes
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
JP6602964B2 (ja) 2015-09-30 2019-11-06 ノバリック ゲーエムベーハー 半フッ素化化合物およびその組成物
CN108349855B (zh) 2015-09-30 2021-07-20 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
EP3203256A1 (en) * 2016-02-02 2017-08-09 B. Braun Melsungen AG Calibration of mri systems using pre-defined concentrations of 19f isotopes as reference
ES2763121T3 (es) 2016-06-23 2020-05-27 Novaliq Gmbh Método de administración tópica
WO2018054932A1 (en) 2016-09-22 2018-03-29 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
ES2957559T3 (es) 2017-04-21 2024-01-22 Dermaliq Therapeutics Inc Composiciones de yodo
WO2018202835A1 (en) 2017-05-05 2018-11-08 Novaliq Gmbh Process for the production of semifluorinated alkanes
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
EP3687496A1 (en) 2017-09-27 2020-08-05 Novaliq GmbH Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
CN112135603B (zh) 2018-03-02 2024-04-16 诺瓦利克有限责任公司 包含奈必洛尔的药物组合物
JP7360452B2 (ja) 2018-09-27 2023-10-12 ダーマリック セラピューティクス， インコーポレーテッド 脂質バリアの修復
AU2019345929B2 (en) 2018-09-27 2022-02-03 Dermaliq Therapeutics, Inc. Topical sunscreen formulation
CN112823020A (zh) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
RU2723391C1 (ru) * 2019-09-19 2020-06-11 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ определения тромбоза ушка левого предсердия по данным контрастной трансторакальной эхокардиографии

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2054658T3 (es) 1986-01-24 1994-08-16 Childrens Hosp Medical Center Metodo para la preparacion de una emulsion fisiologicamente aceptable.
US5171755A (en) * 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
DE4405627A1 (de) * 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US7220401B2 (en) * 1999-09-24 2007-05-22 Barnes-Jewish Hospital Blood clot-targeted nanoparticles
IL163937A0 (en) 2002-03-07 2005-12-18 Univ Carnegie Mellon Contrast agents for magnetic resonance imaging andmethods realted thereto
EP2319544A1 (en) * 2004-01-16 2011-05-11 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
RU2262920C1 (ru) * 2004-09-28 2005-10-27 Открытое Акционерное Общество "Фаберлик" Водная эмульсия перфторсоединений для косметических и/или дерматологических препаратов и способ ее получения
EP1885243A4 (en) 2005-05-11 2014-05-21 Univ Minnesota METHODS AND DEVICE FOR REPRESENTING MAGNETIC INDUCTION
DE102007015598A1 (de) 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
CA2788060C (en) * 2010-03-17 2017-07-11 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
JP6073244B2 (ja) 2011-01-04 2017-02-01 ノバリック ゲーエムベーハー 部分フッ素化アルカンを含むｏ／ｗエマルション
US20130280170A1 (en) * 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy

Also Published As

Publication number Publication date
WO2014154531A1 (en) 2014-10-02
EP2978455A1 (en) 2016-02-03
TW201524521A (zh) 2015-07-01
IL239203A0 (en) 2015-07-30
PL2978455T3 (pl) 2017-06-30
RU2015130915A3 (es) 2018-03-19
US20230355810A1 (en) 2023-11-09
RU2672588C2 (ru) 2018-11-16
HUE030818T2 (en) 2017-06-28
DK2978455T3 (en) 2017-03-06
KR102210774B1 (ko) 2021-02-02
JP6356780B2 (ja) 2018-07-11
IL239203A (en) 2017-03-30
KR20150132836A (ko) 2015-11-26
CA2893799C (en) 2021-03-09
JP2016515553A (ja) 2016-05-30
TWI652069B (zh) 2019-03-01
CN105142681B (zh) 2019-03-12
RU2015130915A (ru) 2017-04-27
BR112015017572A2 (pt) 2017-07-11
PT2978455T (pt) 2017-02-24
ES2616884T3 (es) 2017-06-14
EP2978455B1 (en) 2017-01-04
MX2015013746A (es) 2016-02-26
EP2783703A1 (en) 2014-10-01
CN105142681A (zh) 2015-12-09
US20160000941A1 (en) 2016-01-07
CA2893799A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
MX362702B (es) Compuesto de semifluorocarbono que contiene agente de contraste.
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
AR104725A1 (es) Composiciones surfactantes y detergentes que contienen glicerina etoxilada
IN2015MN00404A (es)
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
BR112016023676A2 (pt) pó de sinterização com baixa pressão
BR112016000299A8 (pt) composições, uso de uma composição, método para o combate dos fungos fitopatogênicos e uso dos componentes
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
ECSP15043280A (es) Nuevos compuestos y composiciones para la inhibición de fasn
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
PH12019501178A1 (en) Thiopene derivatives as antiviral agents
BR112015020555A2 (pt) método de alisamento de cabelo
MX2015008766A (es) Compuestos cbd fluorados, composiciones y usos de los mismos.
PH12019501362A1 (en) Polymorphs
EA201690911A1 (ru) Соединения диметилбензойной кислоты
BR112016008736A2 (pt) formulação estável de insulina glulisina
BR112016024238A2 (pt) uso de composições aquosas de redução de desvio
PH12020550947A1 (en) Polymorphs
AR101136A1 (es) Proceso para la preparación de ácidos 3-hidroxipicolínicos
BR112015011351A2 (pt) composição farmacêutica de difenidol de liberação sustentada
MX2015014531A (es) Composicion que contiene una emulsion, la fase oleosa que comprende un compuesto que consiste de un elastomero de silicona y un tensioactivo, un polvo de elastomero de silicona y un polialquil (met) acrilato.
MX337130B (es) Compuesto organoleptico novedoso.
RU2012113763A (ru) Ненасыщенные блок-сополиэфирсульфоны

Legal Events

Date Code Title Description
FG Grant or registration